PrenatalSAFE® is a non-invasive prenatal screening test which analyses cell-free fetal DNA isolated from a maternal blood sample to provides 6 levels of detailed information of a pregnancy. The screening test allows the detection of aneuploidies, microdeletion syndromes from the most common to the rarest, structural alterations in all the chromosomes of the fetus and the presence of mutations related to serious genetic diseases.
PrenatalSAFE® is offered by the Eurofins Genoma Group laboratories with an option to choose from six levels of prenatal screening, each with a different level of detail.
The most technologically advanced non-invasive prenatal screening test currently available
By analysing the cell-free fetal DNA (cfDNA) circulating in the mother's blood, this new non-invasive prenatal test is able to screen fetal karyotype and serious genetic diseases in the fetus. PrenatalSAFE® Complete in its "Plus" version also detects the 9 most common microdeletion syndromes.
Screens aneuploidy and structural chromosomal alterations (segmental deletions and duplications) of every chromosome. Moreover, it allows identifying the 9 most common microdeletion syndromes in the fetus under PrenatalSafe Karyo Plus screening.
Screens the aneuploidies of chromosomes 21, 18, 13 and sex chromosomes as well as the trisomy of chromosomes 9 and 16. The test also detects the presence of the 6 most common microdeletion syndromes.
Screens the aneuploidies of chromosomes 21, 18, 13, sex chromosomes (X and Y), and includes the determination of fetal sex (optional).
Screens the aneuploidies of chromosomes 21, 18, 13, and includes the determination of fetal sex (optional).
PrenatalSAFE® can be combined with the RhSafe® test, a non-invasive prenatal examination that, by analysing fetal DNA isolated from a blood sample of the pregnant woman, allows to determine the Fetal Rh(D) factor. The RhSafe® test is optional and is performed on request in case of Rh(D) negative pregnant women with Rh(D) positive partner.